Napke E, Stevens D G
Can Med Assoc J. 1984 Dec 15;131(12):1449-52.
The excipients and additives in drug formulations have been described as inert because they do not have an active role in the prevention or treatment of particular ailments. This has led to the misconception among physicians, pharmacists, drug manufacturers and the public that excipients are harmless and unworthy of mention. In fact, pharmacists are allowed to substitute drug formulations, without regard to the excipients, as long as they ensure that the active ingredients in the substitute are the same as those in the formulation prescribed. The inappropriateness of the term inert is becoming increasingly apparent as evidence of adverse reactions--some fatal--to excipients mounts. The likelihood that some "active" constituents, particularly erythromycin, have been blamed for such reactions deserves to be investigated. The public deserves to be better protected. For example, the United States has legislation requiring complete labelling of all food, drugs and cosmetics that incorporate more than one ingredient, no matter how innocuous the constituents are believed to be. In Canada, drug manufacturers are not even required to share this information with physicians or pharmacists when they introduce a new drug or reformulate a product already being marketed, nor are pharmacists required to disclose the contents of formulations that they prepare in the absence of commercially available products.
药物制剂中的辅料和添加剂一直被认为是惰性的,因为它们在预防或治疗特定疾病方面没有积极作用。这导致医生、药剂师、药品制造商和公众产生了一种误解,认为辅料是无害的,不值得一提。事实上,只要药剂师确保替代药物制剂中的活性成分与处方制剂中的活性成分相同,他们就可以在不考虑辅料的情况下替换药物制剂。随着辅料不良反应(有些是致命的)证据的增加,“惰性”这个词的不恰当性越来越明显。一些“活性”成分,特别是红霉素,被指责导致此类反应,这一可能性值得研究。公众应该得到更好的保护。例如,美国有立法要求对所有含有多种成分的食品、药品和化妆品进行完整标注,无论这些成分被认为多么无害。在加拿大,药品制造商在推出新药或重新配制已上市产品时,甚至无需与医生或药剂师分享这些信息,药剂师也无需披露他们在没有市售产品时配制的制剂内容。